Boltwood Capital Management cut its stake in Merck & Company, Inc. (NYSE:MRK) by 2.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the company’s stock after selling 300 shares during the period. Boltwood Capital Management’s holdings in Merck & were worth $640,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. Gradient Investments LLC raised its holdings in Merck & by 41.3% in the 1st quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock valued at $147,000 after acquiring an additional 674 shares in the last quarter. Carlson Capital Management raised its holdings in Merck & by 4.5% in the 1st quarter. Carlson Capital Management now owns 3,692 shares of the company’s stock valued at $235,000 after acquiring an additional 159 shares in the last quarter. CrestPoint Capital Management LLC raised its holdings in Merck & by 3.5% in the 1st quarter. CrestPoint Capital Management LLC now owns 29,400 shares of the company’s stock valued at $1,868,000 after acquiring an additional 1,000 shares in the last quarter. First PREMIER Bank raised its holdings in Merck & by 2.7% in the 1st quarter. First PREMIER Bank now owns 21,475 shares of the company’s stock valued at $1,364,000 after acquiring an additional 570 shares in the last quarter. Finally, First National Bank of Omaha raised its holdings in Merck & by 1.5% in the 1st quarter. First National Bank of Omaha now owns 50,293 shares of the company’s stock valued at $3,196,000 after acquiring an additional 751 shares in the last quarter. 73.02% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This report was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/09/17/boltwood-capital-management-has-640000-holdings-in-merck-company-inc-mrk.html.
Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Cowen and Company reiterated a “hold” rating and issued a $70.00 price target on shares of Merck & in a research note on Friday, September 1st. Credit Suisse Group reiterated a “buy” rating on shares of Merck & in a research note on Tuesday, June 13th. Jefferies Group LLC reiterated a “sell” rating and issued a $52.00 price target on shares of Merck & in a research note on Sunday, August 20th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $74.00 price target (up previously from $70.00) on shares of Merck & in a research note on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $70.00.
Merck & Company, Inc. (NYSE MRK) traded up 0.06% during midday trading on Friday, hitting $66.16. The company’s stock had a trading volume of 14,685,767 shares. The stock has a 50 day moving average of $63.41 and a 200 day moving average of $63.72. The company has a market cap of $180.44 billion, a PE ratio of 35.82 and a beta of 0.81. Merck & Company, Inc. has a 52-week low of $58.29 and a 52-week high of $66.80.
Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. During the same period last year, the firm earned $0.93 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. On average, equities analysts expect that Merck & Company, Inc. will post $3.87 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.84%. Merck &’s dividend payout ratio (DPR) is currently 76.11%.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.